Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Operations (2021 - 2025)

Historic Cash from Operations for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$1.6 million.

  • InMed Pharmaceuticals' Cash from Operations rose 1199.87% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year decrease of 1369.79%. This contributed to the annual value of -$7.8 million for FY2025, which is 1118.15% down from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Cash from Operations is -$1.6 million, which was up 1199.87% from -$1.8 million recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Cash from Operations peaked at -$657934.0 during Q2 2023, and registered a low of -$5.3 million during Q1 2022.
  • Moreover, its 5-year median value for Cash from Operations was -$1.9 million (2024), whereas its average is -$2.3 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first skyrocketed by 8374.37% in 2023, then plummeted by 7281.07% in 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Cash from Operations (Quarter) stood at -$3.5 million in 2021, then grew by 23.22% to -$2.7 million in 2022, then skyrocketed by 31.88% to -$1.8 million in 2023, then crashed by 35.39% to -$2.5 million in 2024, then soared by 35.75% to -$1.6 million in 2025.
  • Its Cash from Operations stands at -$1.6 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$1.7 million for Q1 2025.